Neogen Corp: Form 10-Q for the period ended Feb 28, 2025
Filed with the SEC on Apr 9, 2025 and accepted by EDGAR at Apr 9, 2025, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-02-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-12-01 to 2025-02-28 | $221.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-06-01 to 2025-02-28 | $669.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-12-01 to 2025-02-28 | $110.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-06-01 to 2025-02-28 | $340.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-12-01 to 2025-02-28 | $110.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-06-01 to 2025-02-28 | $328.5m | us-gaap:GrossProfit |
| Research and development | 3 months2024-12-01 to 2025-02-28 | $4.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-06-01 to 2025-02-28 | $14.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-12-01 to 2025-02-28 | $5.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-06-01 to 2025-02-28 | −$449.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-12-01 to 2025-02-28 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-06-01 to 2025-02-28 | −$22.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-12-01 to 2025-02-28 | −$11.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-06-01 to 2025-02-28 | −$479.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-12-01 to 2025-02-28 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-06-01 to 2025-02-28 | −$2.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-12-01 to 2025-02-28 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-06-01 to 2025-02-28 | −$2.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-12-01 to 2025-02-28 | 217,031,907 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-06-01 to 2025-02-28 | 216,845,782 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-06-01 to 2025-02-28 | $41.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-06-01 to 2025-02-28 | $88.5m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2025-02-28 | $127.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-02-28 | $551.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-02-28 | $4.04bn | us-gaap:Assets |
| Current liabilities | At period end2025-02-28 | $141.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-02-28 | $1.38bn | us-gaap:Liabilities |
| Long-term debt | At period end2025-02-28 | $890.6m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2025-02-28 | $2.66bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-02-28 | 217,038,267 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000950170-25-052497. Last ingested by Listed: Oct 30, 2026, 15:36 ET. Listed shows no prices and gives no investment advice.